Q2 2019 Earnings Estimate for STAAR Surgical (NASDAQ:STAA) Issued By William Blair

STAAR Surgical (NASDAQ:STAA) – Investment analysts at William Blair boosted their Q2 2019 EPS estimates for shares of STAAR Surgical in a research report issued to clients and investors on Thursday, May 2nd, Zacks Investment Research reports. William Blair analyst B. Weinstein now anticipates that the medical instruments supplier will post earnings of $0.10 per share for the quarter, up from their prior forecast of $0.09. William Blair also issued estimates for STAAR Surgical’s FY2019 earnings at $0.39 EPS, Q1 2020 earnings at $0.09 EPS, Q2 2020 earnings at $0.15 EPS, Q3 2020 earnings at $0.15 EPS and Q4 2020 earnings at $0.15 EPS.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.10 EPS for the quarter, topping the consensus estimate of $0.04 by $0.06. The company had revenue of $32.58 million during the quarter, compared to analyst estimates of $32.40 million. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. During the same quarter in the previous year, the firm earned $0.01 EPS.

Several other brokerages have also commented on STAA. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. BidaskClub raised shares of STAAR Surgical from a “hold” rating to a “buy” rating in a report on Friday, March 22nd. ValuEngine lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $38.00 price target (down previously from $43.00) on shares of STAAR Surgical in a report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.33.

NASDAQ STAA traded up $0.61 on Monday, hitting $24.19. The company had a trading volume of 489,819 shares, compared to its average volume of 434,744. The firm has a market cap of $1.08 billion, a PE ratio of 86.39 and a beta of 2.02. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.83 and a current ratio of 5.41. STAAR Surgical has a 12-month low of $21.70 and a 12-month high of $54.00.

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 100,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was acquired at an average price of $22.23 per share, with a total value of $2,223,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samuel J. Gesten sold 1,500 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $36.20, for a total transaction of $54,300.00. Following the sale, the insider now directly owns 36,816 shares of the company’s stock, valued at approximately $1,332,739.20. The disclosure for this sale can be found here. Insiders have sold 17,730 shares of company stock valued at $655,538 in the last ninety days. Insiders own 3.90% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in STAA. AdvisorNet Financial Inc lifted its position in STAAR Surgical by 600.0% in the fourth quarter. AdvisorNet Financial Inc now owns 875 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 750 shares during the last quarter. Mascoma Wealth Management LLC acquired a new position in STAAR Surgical in the first quarter valued at about $38,000. Macquarie Group Ltd. lifted its position in STAAR Surgical by 228.6% in the first quarter. Macquarie Group Ltd. now owns 1,354 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 942 shares during the last quarter. Aspire Private Capital LLC acquired a new position in STAAR Surgical in the first quarter valued at about $51,000. Finally, First Quadrant L P CA acquired a new position in STAAR Surgical in the fourth quarter valued at about $92,000. 89.59% of the stock is owned by hedge funds and other institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

See Also: Catch-Up Contributions

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.